Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Cash Flow (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Net Cash Flow for 12 consecutive years, with -$107.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 366.56% to -$107.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $151.4 million, a 1036.44% increase, with the full-year FY2024 number at -$1.7 million, up 99.32% from a year prior.
  • Net Cash Flow was -$107.2 million for Q3 2025 at Theravance Biopharma, down from $171.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $171.3 million in Q2 2025 to a low of -$758.3 million in Q3 2022.
  • A 5-year average of -$49.6 million and a median of $3.8 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 3014.21% in 2023, then skyrocketed 2387.22% in 2025.
  • Theravance Biopharma's Net Cash Flow stood at $32.5 million in 2021, then surged by 80.07% to $58.6 million in 2022, then crashed by 288.57% to -$110.5 million in 2023, then skyrocketed by 113.05% to $14.4 million in 2024, then plummeted by 843.14% to -$107.2 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Net Cash Flow are -$107.2 million (Q3 2025), $171.3 million (Q2 2025), and $72.8 million (Q1 2025).